AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MetaVia shares surge 126.72% after-hours on positive Phase 1 trial results for DA-1726 obesity drug.
ByAinvest
Friday, Dec 5, 2025 5:50 pm ET1min read
MetaVia Inc. (NASDAQ:MTVA) surged 126.72% in after-hours trading following the announcement of a 1-for-11 reverse stock split, effective December 4, 2025, to comply with Nasdaq’s minimum bid price requirements. The move reduces outstanding shares from ~25.4 million to ~2.3 million, aligning with shareholder-approved measures taken at the June 30, 2025, annual meeting. The reverse split aims to stabilize the stock price, enhance market perception, and ensure continued Nasdaq listing. Fractional shares will be rounded down, with shareholders compensated in cash for any value lost. This strategic action directly addresses recent Nasdaq delisting concerns and is the most immediate catalyst for the stock’s dramatic after-hours rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet